Sage Therapeutics, Inc. (SAGE)

Market Cap	448.99M
Revenue (ttm)	47.40M
Net Income (ttm)	-354.40M
Shares Out	62.62M
EPS (ttm)	-5.79
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	722,068
Open	7.25
Previous Close	7.30
Day's Range	7.17 - 7.35
52-Week Range	4.62 - 14.56
Beta	0.20
Analysts	Hold
Price Target	9.88 (+37.8%)
Earnings Date	Apr 29, 2025

About SAGE

Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes brain health medicines. The company offers ZURZUVAE, a neuroactive steroid positive allosteric modulator of GABA receptors targeting synaptic and extrasynaptic GABA receptors for the treatment of postpartum depression in adults. Its product pipeline also includes SAGE-324, a novel GABA receptor positive allosteric modulator for chronic oral dosing, including seizures in developmental and epileptic encephalopathies; and SAGE-319, an extrasynaptic-preferring GABA re...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jul 18, 2014
• Employees: 353
• Stock Exchange: NASDAQ
• Ticker Symbol: SAGE
• Website: https://www.sagerx.com

Financial Performance

In 2024, Sage Therapeutics's revenue was $41.24 million, a decrease of -52.30% compared to the previous year's $86.46 million. Losses were -$400.67 million, -26.01% less than in 2023.

Analyst Forecast

According to 19 analysts, the average rating for SAGE stock is "Hold." The 12-month stock price forecast is $9.88, which is an increase of 37.80% from the latest price.

Price Target

$9.88

(37.80% upside)

Analyst Consensus: Hold